Gentian Diagnostics ASA (OSL:GENT)

Norway flag Norway · Delayed Price · Currency is NOK
38.90
-0.60 (-1.52%)
At close: Mar 2, 2026
-21.26%
Market Cap 599.93M
Revenue (ttm) 176.50M
Net Income (ttm) 13.26M
Shares Out 15.42M
EPS (ttm) 0.86
PE Ratio 45.26
Forward PE 14.85
Dividend 0.60 (1.52%)
Ex-Dividend Date May 6, 2026
Volume 32,184
Average Volume 43,448
Open 40.00
Previous Close 39.50
Day's Range 38.10 - 40.00
52-Week Range 36.10 - 65.80
Beta 0.44
RSI 27.78
Earnings Date Feb 11, 2026

About Gentian Diagnostics ASA

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chro... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2001
Employees 63
Stock Exchange Oslo Børs
Ticker Symbol GENT
Full Company Profile

Financial Performance

In 2025, Gentian Diagnostics ASA's revenue was 176.50 million, an increase of 16.07% compared to the previous year's 152.07 million. Earnings were 13.26 million, a decrease of -70.73%.

Financial Statements

News

There is no news available yet.